Higher-Affinity Agonists of 5-HT1AR Discovered through Tuning the Binding-Site Flexibility
暂无分享,去创建一个
Peng Lian | Wei Fu | LinLang Li | Chuanrong Geng | Xuechu Zhen | Xuechu Zhen | P. Lian | LinLang Li | W. Fu | Chuanrong Geng
[1] P. Albert,et al. 5-HT1A Receptors, Gene Repression, and Depression: Guilt by Association , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[2] P. Celada,et al. Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research , 2013, CNS Drugs.
[3] S. Dilly,et al. Molecular modeling study of 4-phenylpiperazine and 4-phenyl-1,2,3,6-tetrahydropyridine derivatives: a new step towards the design of high-affinity 5-HT1A ligands. , 2010, Bioorganic & medicinal chemistry letters.
[4] Peng Lian,et al. Simulation Study of Coupling and Uncoupling Mechanisms of Cytochrome P 450 cam , 2013 .
[5] K. Mine,et al. Chronic treatment with tandospirone, a serotonin 1A receptor partial agonist, inhibits psychosocial stress-induced changes in hippocampal neurogenesis and behavior. , 2015, Journal of affective disorders.
[6] Joseph P. Huston,et al. Serotonin and psychostimulant addiction: Focus on 5-HT1A-receptors , 2007, Progress in Neurobiology.
[7] Silvia Franchini,et al. Discovery of a new series of 5-HT1A receptor agonists. , 2010, Bioorganic & medicinal chemistry letters.
[8] Carsten Kutzner,et al. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.
[9] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[10] Jeremy C. Smith,et al. Catalytic mechanism and origin of high activity of cellulase TmCel12A at high temperature: a quantum mechanical/molecular mechanical study , 2014, Cellulose.
[11] Kuo-Chen Chou,et al. An Allosteric Mechanism Inferred from Molecular Dynamics Simulations on Phospholamban Pentamer in Lipid Membranes , 2011, PloS one.
[12] Xuechu Zhen,et al. (6aR)-11-Amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease , 2014, Pharmacology Biochemistry and Behavior.
[13] C. Macedo,et al. Involvement of median raphe nucleus 5-HT1A receptors in the regulation of generalized anxiety-related defensive behaviours in rats , 2008, Neuroscience Letters.
[14] J. Łuszczki,et al. Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1. , 2011, European journal of medicinal chemistry.
[15] H. Watts,et al. Breakthrough Seizures after Starting Vilazodone for Depression , 2015, Pharmacotherapy.
[16] M. Parrinello,et al. Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .
[17] J. Brotchie,et al. Serotonin and Parkinson's disease: On movement, mood, and madness , 2009, Movement disorders : official journal of the Movement Disorder Society.
[18] Bo Gao,et al. Molecular Modeling of the 3D Structure of 5-HT1AR: Discovery of Novel 5-HT1AR Agonists via Dynamic Pharmacophore-Based Virtual Screening , 2013, J. Chem. Inf. Model..
[19] Hoover,et al. Canonical dynamics: Equilibrium phase-space distributions. , 1985, Physical review. A, General physics.
[20] Adriano D Andricopulo,et al. Pharmacophore-based 3D QSAR studies on a series of high affinity 5-HT1A receptor ligands. , 2010, European journal of medicinal chemistry.
[21] S. Nosé. A molecular dynamics method for simulations in the canonical ensemble , 1984 .
[22] Yuxiang Bu,et al. Tethered-hopping model for protein-DNA binding and unbinding based on Sox2-Oct1-Hoxb1 ternary complex simulations. , 2010, Biophysical journal.
[23] Shanglin Zhou,et al. Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. , 2011, Journal of medicinal chemistry.
[24] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[25] O. Berger,et al. Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. , 1997, Biophysical journal.
[26] Hee-Jung Choi,et al. Structural features of β2 adrenergic receptor: crystal structures and beyond. , 2015, Molecules and cells.
[27] Quan Yuan,et al. A Sleep-Promoting Role for the Drosophila Serotonin Receptor 1A , 2006, Current Biology.
[28] Christian Kandt,et al. Setting up and running molecular dynamics simulations of membrane proteins. , 2007, Methods.
[29] A. Bojarski,et al. Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1. , 2013, European journal of medicinal chemistry.
[30] Xuechu Zhen,et al. Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist. , 2010, Journal of medicinal chemistry.
[31] A. W. Schüttelkopf,et al. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.
[32] Xuechu Zhen,et al. Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand , 2009, Schizophrenia Research.
[33] J. Ramos,et al. New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo. , 2013, Journal of medicinal chemistry.
[34] N. Veldman,et al. 5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines. , 1997, Journal of medicinal chemistry.
[35] M. Laruelle,et al. In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue. , 2011, Nuclear medicine and biology.
[36] M F Sanner,et al. Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.
[37] P. Pauwels,et al. Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia , 2002, Neuropharmacology.
[38] A. Andrews,et al. Rethinking 5-HT1A receptors: emerging modes of inhibitory feedback of relevance to emotion-related behavior. , 2013, ACS chemical neuroscience.
[39] S. Nosé,et al. Constant pressure molecular dynamics for molecular systems , 1983 .
[40] R. Stevens,et al. Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.
[41] Hualiang Jiang,et al. Agonist-bound structure of the human P2Y12 receptor , 2014, Nature.
[42] A. Leslie,et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.
[43] H. Berendsen,et al. Interaction Models for Water in Relation to Protein Hydration , 1981 .
[44] M. Thase,et al. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER , 2015, Depression and anxiety.
[45] E. Lacivita,et al. The therapeutic potential of 5-HT1A receptors: a patent review , 2012, Expert opinion on therapeutic patents.
[46] I. Seif,et al. Reduced density of functional 5‐HT1A receptors in the brain, medulla and spinal cord of monoamine oxidase‐A knockout mouse neonates , 2006, The Journal of comparative neurology.
[47] Xuechu Zhen,et al. l-Stepholidine reduced l-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease , 2010, Neurobiology of Aging.